LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage
Haematology/Oncology; Pathology and Laboratory Medicine; Community Health Sciences
Multiple myeloma (MM) is a heterogeneous disease of the bone marrow (BM). Its association with Epstein-Barr virus (EBV) remains enigmatic. Aim of our study was to determine expression of latent membrane protein 1 (LMP1), aldehyde dehydrogenase 1 (ALDH1), CD117 and their association with 5-year survival in MM patients. Seven percent of cases expressed LMP1 in MM cells with no association with survival. Whereas, LMP1 expression in CD138- non-neoplastic cells was observed in 80% of the cases, conferring a survival advantage of 1.75 years (mean 3.75 ± 0.28, 95% CI 3.19-4.3). LMP1 in CD138- non-neoplastic cells was associated with CD117 expression in MM cells. Combinatorial analysis of LMP1 and CD117 stratified patients into good prognostic group LMP1+/CD117- (mean survival 4.16 ± 0.39 years) and a worst prognostic group; LMP1-/CD117+ (mean survival 1.02 ± 0.29 years). Our study showed that LMP1 expression in CD138- non-neoplastic cells of BM in MM patients confers a survival advantage.
Leukemia & Lymphoma
Syed, I. A.,
(2019). LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage. Leukemia & Lymphoma, 60(8), 1991-2001.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1204